Guiqing Ding

Guiqing Ding

Auto-generated profile, based on publicly available information

Guiqing Ding

Institute of Clinical Immunology, Yue‐Yang Hospital of Integrative Medicine Shanghai University of Traditional Chinese Medicine Shanghai China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
GDGuiqing Ding
Guiqing Ding
QGQianyi Gong
Qianyi Gong
JMJinyun Ma
Jinyun Ma
XLXiaojun Liu
Xiaojun Liu
YWYuanhua Wang
Yuanhua Wang
XCXiaodong Cheng
Xiaodong Cheng
Astragalus polysaccharides (APS), the main effective component of Astragalus membranaceus, can inhibit tumor growth, but the underlying mechanisms remain unclear. Previous studies have suggested that APS can regulate the gut microenvironment, including the gut microbiota and fecal metabolites. In this work, our results showed that APS could control tumor growth in melanoma‐bearing mice. It could reduce the number of myeloid‐derived suppressor cells (MDSC), as well as the expression of MDSC‐related molecule Arg‐1 and cytokines IL‐10 and TGF‐β, so that CD8+ T cells could kill tumor cells more effectively. However, while APS were administered with an antibiotic cocktail (ABX), MDSC could not be reduced, and the growth rate of tumors was accelerated. Consistent with the changes in MDSC, the serum levels of IL‐6 and IL‐1β were lowest in the APS group. Meanwhile, we found that fecal suspension from mice in the APS group could also reduce the number of MDSC in tumor tissues. These results revealed that APS regulated the immune function in tumor‐bearing mice through remodeling the gut microbiota. Next, we focused on the results of 16S rRNA, which showed that APS significantly regulated most microorganisms, such as Bifidobacterium pseudolongum, Lactobacillus johnsonii and Lactobacillus. According to the Spearman analysis, the changes in abundance of these microorganisms were related to the increase of metabolites like glutamate and creatine, which could control tumor growth. The present study demonstrates that APS attenuate the immunosuppressive activity of MDSC in melanoma‐bearing mice by remodeling the gut microbiota and fecal metabolites. Our findings reveal the therapeutic potential of APS to control tumor growth.

1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
XLXiaojun Liu
Xiaojun Liu
JMJinyun Ma
Jinyun Ma
GDGuiqing Ding
Guiqing Ding
QGQianyi Gong
Qianyi Gong
YWYuanhua Wang
Yuanhua Wang
XCXiaodong Cheng
Xiaodong Cheng
Activated microglia is considered to be major mediators of the neuroinflammatory environment in demyelinating diseases of the central nervous system (CNS). Activated microglia are mainly polarized into M1 type, which plays a role in promoting inflammation and demyelinating. However, the proportion of microglia polarized into M2 type is relatively low, which cannot fully play the role of anti‐inflammatory and resistance to demyelinating. Our previous study found that Astragalus polysaccharides (APS) has an immunomodulatory effect and can inhibit neuroinflammation and demyelination in experimental autoimmune encephalomyelitis (EAE), which is a classic animal model of CNS demyelinating disease. In this study, we found that APS was effective in treating EAE mice. It restored microglia balance by inhibiting the polarization of microglia to M1‐like phenotype and promoting the polarization of microglia to M2‐like phenotype in vivo and in vitro. miR‐155 is a key factor in regulating microglia polarization. We found that APS could inhibit the expression level of miR‐155 in vivo and in vitro. Furthermore, we performed transfection overexpression and blocking experiments. The results showed that miR‐155 mediated the polarization of microglia M1/M2 phenotype, while the selective inhibitor of miR‐155 attenuated the inhibition of APS on microglia M1 phenotype and eliminated the promotion of APS on microglia M2 phenotype. Microglia can secrete IL‐1α, TNF‐α, and C1q after polarizing into M1 type and induce the activation of A1 neurotoxic astrocytes, further aggravating neuroinflammation and demyelination. APS reduced the secretion of IL‐1α, TNF‐α, and C1q by activated microglia, thus inhibited the formation of A1 neurotoxic astrocytes. In summary, our study suggests that APS regulates the polarization of microglia from M1 to M2 phenotype by inhibiting the miR‐155, reduces the secretion of inflammatory factors, and inhibits the activation of neurotoxic astrocytes, thus effectively treating EAE.

23 February 2024 in Future Oncology
Verified
Journal Article
Closed access
GDGuiqing Ding
Guiqing Ding
HYHua Yu
Hua Yu
JJJason Jin
Jason Jin
XQXi Qiao
Xi Qiao
JMJinyun Ma
Jinyun Ma
XCXiaodong Cheng
Xiaodong Cheng
Recently, there has been an increased focus on cancer stem cells (CSCs) due to their resilience, making them difficult to eradicate. This resilience often leads to tumor recurrence and metastasis. ... Plain language summary Cancer stem cells (CSCs) are a kind of tumor cell. These cells are hard to kill but contribute to tumor progression and metastasis. Myeloid-derived suppressor cells (MDSCs) e...

14 April 2026 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
XQXi Qiao
Xi Qiao
GDGuiqing Ding
Guiqing Ding
QLQijin Lu
Qijin Lu
YCYuxin Chen
Yuxin Chen
XWXiaohan Wang
Xiaohan Wang
XCXiaodong Cheng
Xiaodong Cheng
Astragalus polysaccharides (APS) exhibits potent immunomodulatory properties, yet its interplay with intratumoral microbiota in driving antitumor immunity remains elusive. Herein, we demonstrate that APS suppresses melanoma growth and prolongs survival by inducing immunogenic cell death (ICD) via the cGAS‐STING pathway. Inhibition of cGAS‐STING abrogated APS efficacy. Notably, depletion of intratumoral microbiota using antibiotics blunted APS‐mediated cGAS‐STING activation and immune responses, confirming a microbiota‐dependent mechanism. 5R 16S rRNA sequencing identified Pseudomonas enrichment as a distinct signature of APS treatment. Crucially, administration of Pseudomonas sterile supernatant was sufficient to activate cGAS‐STING signaling, induce ICD, and inhibit tumor growth in microbiota‐depleted mice. We propose that APS acts as an upstream modulator that enriches Pseudomonas, creating a microenvironment where bacterial secretions trigger the cGAS‐STING pathway to induce ICD. These findings provide a novel theoretical basis for microbiota‐targeted immunotherapies.